Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
Andrew R. Clamp, Jonathan A. Ledermann(Cancer Institute (WIA)), Adrian Cook(University College London), Marcia Hall(Hillingdon Hospitals NHS Foundation Trust), Sally Stenning(Medical Research Council), Hani Gabra(Royal Children's Hospital), Gosala Gopalakrishnan(MRC Clinical Trials Unit at UCL), Timothy Perren(Royal Marsden NHS Foundation Trust), Sarah Williams(Birmingham City Hospital), Rosalind Glasspool(Institut Bergonié), Graham Dark(Freeman Hospital), Jae‐Weon Kim(Seoul National University Hospital), James D. Brenton(University of Cambridge), Andrew Dean, Richard Kaplan(University College London), Sudha Sundar(Sandwell & West Birmingham Hospitals NHS Trust), Susana Banerjee(Royal Marsden NHS Foundation Trust), Sarah P. Blagden(Churchill Hospital), Elizabeth C James(MRC Clinical Trials Unit at UCL), Ann Marie Swart(University of East Anglia), Helena Earl(University of Cambridge), Raj Naik(Queen Elizabeth Hospital), Rachel Jones(Velindre Cancer Centre), Iain A. McNeish(Beatson West of Scotland Cancer Centre), Christopher Coyle(University of Otago), Dearbhaile M. O’Donnell, Rosemary Lord(Clatterbridge Cancer Centre NHS Foundation Trust), Jane Hook(University of Leeds), Mahesh Parmar(University College London)
Cited by 223
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k